Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.
A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
Patients with advanced sarcoma who developed immune-related adverse events after immune checkpoint blockade were more likely to have a clinical benefit.
A phase 2 trial is under way to evaluate an investigational autologous T-cell product in patients with advanced synovial sarcoma as well as other tumor types.
A single-arm phase II clinical trial is underway to evaluate temozolomide and olaparib as a treatment combination for patients with advanced uterine leiomyosarcoma.